ClariVest Asset Management’s Maravai LifeSciences MRVI Stock Holding History

ClariVest Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-88,551	Closed	-$2.52M	–	734
2022 Q2	$2.52M	Sell	88,551 -23,500	-21%	-$744K	0.11%	159
2022 Q1	$3.95M	Sell	112,051 -600	-0.5%	-$20.1K	0.16%	133
2021 Q4	$4.72M	Sell	112,651 -11,100	-9%	-$450K	0.15%	139
2021 Q3	$6.07M	Buy	123,751 +58,100	+88%	+$2.83M	0.2%	108
2021 Q2	$2.74M	Sell	65,651 -403	-0.6%	-$15.6K	0.09%	193
2021 Q1	$2.35M	Buy	+66,054	New	+$2.19M	0.08%	196

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

ClariVest Asset Management's MRVI Position: Q3 2022 in Review

ClariVest Asset Management sold out of Maravai LifeSciences (MRVI) in Q3 2022, closing a stake of 88,551 shares — an estimated $2.52M sold.

ClariVest Asset Management first reported a position in MRVI in Q1 2021 and held it in 6 quarters. The position peaked at $6.07M in Q3 2021. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

ClariVest Asset Management reported no remaining Maravai LifeSciences position as of Q3 2022 after selling out during the quarter.
ClariVest Asset Management sold 88,551 Maravai LifeSciences shares in Q3 2022, an estimated $2.52M.
ClariVest Asset Management first reported a position in Maravai LifeSciences in Q1 2021 and held it in 6 quarters.
ClariVest Asset Management's Maravai LifeSciences position peaked at $6.07M in Q3 2021.
202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on ClariVest Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.